CTI Biopharma Corp
F:CEPS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
CTI Biopharma Corp
Inventory
CTI Biopharma Corp
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CTI Biopharma Corp
F:CEPS
|
Inventory
$777k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
-10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$4.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Inventory
$4.4B
|
CAGR 3-Years
44%
|
CAGR 5-Years
34%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Inventory
$6.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Inventory
$1.6B
|
CAGR 3-Years
61%
|
CAGR 5-Years
46%
|
CAGR 10-Years
42%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Inventory
$2.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
29%
|
|
CTI Biopharma Corp
Glance View
CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.
See Also
What is CTI Biopharma Corp's Inventory?
Inventory
777k
USD
Based on the financial report for Mar 31, 2023, CTI Biopharma Corp's Inventory amounts to 777k USD.
What is CTI Biopharma Corp's Inventory growth rate?
Inventory CAGR 10Y
-10%
Over the last year, the Inventory growth was 662%.
